Indaptus Therapeutics filings document a clinical-stage biotechnology issuer developing Decoy20 and related immunotherapy programs for cancer and viral infections. The company’s regulatory record includes material-event reports, proxy statements, capital-structure disclosures, and governance filings tied to its Nasdaq-listed common stock.
Key filing subjects include convertible preferred stock, warrants, warrant repricing agreements, voting agreements, unregistered securities, shareholder meeting proposals, and changes in control. The filings also cover board and officer appointments or resignations, compensatory arrangements, operating and financial results, and material agreements that affect the company’s financing, governance, and public-company structure.
Indaptus Therapeutics, Inc. (INDP) is the issuer for which Sino Lion Ventures Limited reports beneficial ownership of 38,895,000 common shares, or 25.325% of the class. Chenhao Xu, Sino Lion’s controlling person, reports shared voting and dispositive power over the same shares but disclaims beneficial ownership except to the extent of his pecuniary interest.
The reported ownership percentage decreased by more than 1% solely because 20,338,974 shares were issued or issuable in connection with Indaptus’ private placement closing on October 16, 2026; the reporting persons did not acquire or dispose of shares in connection with it. The percentage uses 153,581,298 shares outstanding, including 133,242,324 outstanding as of August 13, 2026. The 38,895,000 shares were issued upon conversion of Series AA and Series AAA preferred stock at the March 23, 2026 closing of a purchase agreement dated March 19, 2026.
Indaptus Therapeutics, Inc. (INDP) reports that Junyi Dai, its chief executive officer and chairman, beneficially owns 11,250,000 shares of common stock, representing 7.325% of the outstanding shares. The amendment says his ownership percentage declined by more than 1% solely because of the October 16, 2026 private placement, which involved 20,338,974 shares issued or issuable; Dai did not acquire or dispose of common shares in connection with it.
Dai’s shares were issued upon conversion of Series AA and Series AAA preferred stock in connection with the March 23, 2026 closing. He used $1,156,642.43 of personal funds to purchase Series AAA preferred stock under the March 19, 2026 purchase agreement. The reported percentage uses 153,581,298 shares outstanding, including 133,242,324 shares outstanding as of August 13, 2026, and the private-placement shares. Dai reported no common-stock transactions during the past 60 days.
Indaptus Therapeutics, Inc. (INDP) reports that Yun Yao, a private investor, beneficially owns 41,991,000 shares, or 27.34% of the common stock. Her reported ownership percentage decreased by more than 1% solely because of the issuer’s October 16, 2026 private placement; Yao did not acquire or dispose of common shares in connection with it. The ownership calculation uses 153,581,298 shares, including 20,338,974 shares issued or issuable upon closing of the placement.
Yao’s shares were issued upon conversion of Series AA and Series AAA Preferred Stock in connection with the transaction closing on March 23, 2026. She used $4,317,206.43 in personal funds to purchase Series AAA Preferred Stock under the related purchase agreement.
Indaptus Therapeutics, Inc. (INDP) reported that investor Ting Yang sold an aggregate of 1,301,827 common shares in unsolicited brokers’ transactions in the open market since June 26, 2026. After the sales and the October 16, 2026 private-placement closing, Yang reported beneficial ownership of 9,948,173 shares, or approximately 6.48%.
The percentage is based on 153,581,298 shares, comprising 133,242,324 shares outstanding as of August 13, 2026, plus 20,338,974 shares issued or issuable in connection with the private placement. Yang reported sole voting and dispositive power over his shares: 2,448,173 are held in a brokerage account and 7,500,000 in book-entry form on the issuer’s transfer-agent records.
Indaptus Therapeutics, Inc. (INDP) completed a private placement of 20,338,974 shares of common stock for aggregate gross proceeds of approximately $24.0 million, before deducting offering expenses. On October 16, 2026, the company received the full purchase price from each purchaser and stated it will issue the shares in connection with closing.
The Stock Purchase Agreement was dated September 8, 2026. The outside date applicable to each purchaser was extended from September 29, 2026, to October 16, 2026.
Indaptus Therapeutics, Inc. and the purchasers in its private placement extended each purchaser’s closing deadline from September 29, 2026 to October 16, 2026. Indaptus may defer and coordinate closings until the applicable purchase-agreement conditions are satisfied or waived, but no later than October 16, unless the company and the applicable purchaser agree otherwise in writing. The purchaser funding deadline and certain related termination rights were also extended to October 16.
Under the September 8, 2026 Purchase Agreement, Indaptus agreed to issue and sell common stock in a private placement for approximately $24.0 million in aggregate gross proceeds, before offering expenses.
Indaptus Therapeutics, Inc. (INDP) entered into a Stock Purchase Agreement on September 8, 2026 to conduct a private placement of 20,338,974 shares of common stock for aggregate gross proceeds of approximately $24.0 million, before expenses. The purchase price per share equals the “Nasdaq Minimum Price,” as defined in the agreement, plus $0.015 per share.
The company currently intends to use the net proceeds for working capital, research and development and other general corporate purposes, including potential early-stage research and preclinical evaluation of a neurotechnology and neural-network-based device for certain sleep-related conditions. Closing is subject to customary conditions and is expected to occur within up to fifteen business days after September 8, 2026, and the company has agreed to seek registration of the resale of the shares after closing.
Indaptus Therapeutics, Inc. (INDP) amended its at-the-market equity program by entering into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright & Co. on August 28, 2026. The program permits Indaptus to sell shares of common stock with an aggregate maximum gross sales price of $100,000,000 through or to H.C. Wainwright as sales agent or principal, subject to share-authorization and Form S-3 eligibility limits; this $100,000,000 cap applies only to shares sold after the new agreement’s execution date.
Sales will be made under an ATM prospectus supplement and base prospectus forming part of Indaptus’s shelf registration statement on Form S-3, and Indaptus will pay H.C. Wainwright a 3.0% placement fee on shares sold when it acts as sales agent. Indaptus retains discretion over whether to sell shares, may set daily share and price parameters, and may suspend the program at any time.
Indaptus Therapeutics, Inc. (INDP) announced that on September 2, 2026, director Tim Ruan notified the company’s Board of Directors of his resignation, effective immediately. The company states that his resignation was not due to any disagreement regarding operations, policies, or practices.
The report is signed on behalf of Indaptus Therapeutics, Inc. by Chief Executive Officer Junyi Dai. Indaptus’s common stock, with a par value of $0.01 per share, is listed on the Nasdaq Capital Market under the symbol INDP.
Indaptus Therapeutics, Inc. (INDP) filed an amendment to its at-the-market offering prospectus covering the potential sale of up to $100,000,000 of common stock under an Amended and Restated At-The-Market Offering Agreement with H.C. Wainwright & Co. The amendment’s sole purpose is to fully replace and correct the prior dilution section, fixing clerical errors in the June 30, 2026 net tangible book value calculations and related dilution figures. As of this amendment, no shares have been sold under the program. Based on an assumed sale at $1.14 per share, pro forma net tangible book value would rise from $0.09 to $0.49 per share, implying illustrative dilution of $0.65 per share to new investors.